RETRACTED ARTICLE: Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study
| Autor: | Mohamed Elbahnasawy, Rehab Badawi, Shaimaa Soliman, Manal H El-Sayed, Hany Dabbous, Ahmed F Sherief, Fatma F S Ebeid, Mohamed Awad Tageldin, Sherief Abd-Elsalam, Mohamed Samir Abd El Ghafar |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Mechanical ventilation
0303 health sciences medicine.medical_specialty 2019-20 coronavirus outbreak Coronavirus disease 2019 (COVID-19) 030306 microbiology medicine.medical_treatment General Medicine Biology Favipiravir Virology law.invention Clinical trial 03 medical and health sciences Randomized controlled trial law Chloroquine Internal medicine medicine Hospital stay 030304 developmental biology medicine.drug |
| Zdroj: | Archives of Virology. 166:949-954 |
| ISSN: | 1432-8798 0304-8608 |
| DOI: | 10.1007/s00705-021-04956-9 |
| Popis: | No specific antiviral drugs have been approved for the treatment of COVID-19. This study aimed to evaluate the efficacy of favipiravir in treatment of COVID-19. This was a multicenter randomized controlled study including 96 patients with COVID- 19 who were randomly assigned into a chloroquine (CQ) group and a favipiravir group. None of the patients in the favipiravir group needed mechanical ventilation (p = 0.129). One patient (2.3%) in the favipiravir group and two patients (4.2%) in the CQ group died (p = 1.00). Favipiravir is a promising drug for COVID-19 that decreases the hospital stay and the need for mechanical ventilation.ClinicalTrials.gov Identifier NCT04351295. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink